ISCF Medicines Manufacturing Round 2 Challenge Fund Competition - Engagement Workshop
An engagement event to update companies, academics & organisations looking to put proposals in the £10m Round 2 Medicines Manufacturing Challenge Fund call.
A further round of £10m funding call for innovative projects in medicines manufacturing opens on 12th March. This funding comes from Wave 1 of the ISCF Leading Edge Healthcare Challenge.
The KTN is working with Innovate UK on an engagement event to update companies, academics and organisations looking to put proposals into this call.
Join Innovate UK and the KTN at this event in York where you will have the opportunity to hear the latest on this as well as pitch for partners and network with others in the sector. Some scope details are listed below and or read the full document here. There will also be an Innovate UK run webinar on 20 March for the official competition launch –register here.
This competition aims to stimulate the development of innovative methods or technologies to improve the manufacture of novel medicines for human use.
‘Novel’ medicines are those that have not yet been commercially launched on the market but may have been applied as part of clinical trials or under exemptions from the UK Human Medicines Regulations.
Proposals can include, but are not limited to, approaches that have the potential to deliver:
· improved commercially viable manufacturing processes
· methods for the reliable and robust scale-up of production of novel medicines
· increased yield of active ingredient
· lower cost of production and goods
In each case there must be reason to expect an improvement in excess of 25%. Small incremental improvements will be deemed to be outside scope.
In this competition medicines that are in scope and can be used as examplar products are limited to:
· advanced therapy medicinal products
· natural product medicines
· nucleic acid-based drugs
· prophylactic vaccines
· protein or peptide biopharmaceuticals
· small molecular weight pharmaceuticals
· virus and phage therapeutics